TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8803649

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (up to 150 mg/day as a single bedtime dose)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Imipramine (240 mg/day on a twice‐daily schedule)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 150
Study: 1535580

Group type: EXPERIMENTAL
Intervention: Marvelon (150 micrograms desogestrel + 30 micrograms ethinyloestradiol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mercilon (150 micrograms desogestrel + 20 micrograms ethinyloestradiol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Microgynon (150 micrograms levonorgestrel + 30 micrograms ethinyloestradiol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Desogestrel OCs (Marvelon and Mercilon)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Microgynon
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All OCs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Marvelon and Mercilon
Number of subjects: 0
Study: 6705695

Group type: EXPERIMENTAL
Intervention: Two-cavity radical operation
Number of subjects: 54

Group type: COMPARATOR
Intervention: Blunt oesophagectomy without thoracotomy
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 54

Group type: COMPARATOR
Intervention: No postoperative radiotherapy
Number of subjects: 54
Study: 30499157

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 28952887

Group type: EXPERIMENTAL
Intervention: Early outpatient palliative care consultations
Number of subjects: 142

Group type: COMPARATOR
Intervention: Delayed outpatient palliative care consultations
Number of subjects: 142
Study: 27153823

Group type: EXPERIMENTAL
Intervention: 3D regimen with ribavirin (N = 615)
Number of subjects: 1690

Group type: EXPERIMENTAL
Intervention: 3D regimen
Number of subjects: 1690
Study: 24668660

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg for normal/mildly impaired renal function
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg for moderate renal impairment
Number of subjects: 161

Group type: COMPARATOR
Intervention: Warfarin (control)
Number of subjects: 161
Study: 22229758

Group type: EXPERIMENTAL
Intervention: SC + CM reinforcing submission of negative samples with $250 in prizes ($250Abs)
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: SC + CM reinforcing attendance ($250Att)
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: $560Abs (higher magnitude CM for initially cocaine-positive patients)
Number of subjects: 442

Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 442
Study: 21125739

Group type: EXPERIMENTAL
Intervention: Polish adaptation of the Visual Function Questionnaire (VFQ-25)
Number of subjects: 108
Study: 17989110

Group type: EXPERIMENTAL
Intervention: Pharmacogenetic-guided dosing
Number of subjects: 206

Group type: COMPARATOR
Intervention: Standard dosing
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Pharmacogenetic-guided dosing (wild-type patients)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Standard dosing (wild-type patients)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Pharmacogenetic-guided dosing (multiple variant carriers)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Standard dosing (multiple variant carriers)
Number of subjects: 206
Study: 16301267

Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve blockade (CFNB) with bupivacaine 0.2% (median infusion rate 9.3 mL/h)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Continuous epidural analgesia (CEA) with ropivacaine 0.2% and fentanyl 4 microg/mL (median infusion rate 7.6 mL/h)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: CFNB group
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 108
Study: 11973207

Group type: EXPERIMENTAL
Intervention: Core temperature of 34 degrees C (mild hypothermia)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Core temperature of 37 degrees C (normothermia)
Number of subjects: 40
Study: 9803099

Group type: EXPERIMENTAL
Intervention: Calcium alginate (Sorbsan)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Paraffin gauze/cotton gauze roll
Number of subjects: 50
Study: 8572630

Group type: EXPERIMENTAL
Intervention: MMV (Mitomycin C, Methotrexate, Vincristine)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: MMVM (MMV + Medroxyprogesterone Acetate)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: MMVP (MMV + Prednisolone)
Number of subjects: 108
Study: 2360833

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 8
Study: 391342

Group type: EXPERIMENTAL
Intervention: Trimipramine (tricyclic antidepressant; mean dose 106 mg at night)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Monoamine oxidase inhibitors (MAOIs; phenelzine mean dose 45 mg/day, isocarboxazid mean dose 32 mg/day)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Combined treatment (phenelzine plus trimipramine or isocarboxazid plus trimipramine)
Number of subjects: 135
Study: 31964186

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Moderate continuous training (MCT)
Number of subjects: 19
Study: 30282088

Group type: COMPARATOR
Intervention: Tissue-level implants restored by platform matching (control)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Bone-level implants restored by platform switching (test)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Comparison between groups
Number of subjects: 35
Study: 28957381

Group type: EXPERIMENTAL
Intervention: Appointment tracking and community outreach systems
Number of subjects: 3149

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 3149
Study: 26576815

Group type: EXPERIMENTAL
Intervention: Klar bleiben intervention (75 classes)
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Control group (75 classes)
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Klar bleiben intervention
Number of subjects: 3000
Study: 23442203

Group type: EXPERIMENTAL
Intervention: Computer game-based learning method
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional learning method
Number of subjects: 0
Study: 21521913

Group type: EXPERIMENTAL
Intervention: Nanoionomer
Number of subjects: 30

Group type: COMPARATOR
Intervention: Resin‐modified glass ionomer
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional glass ionomer cement
Number of subjects: 30
Study: 20302221

Group type: EXPERIMENTAL
Intervention: 1% acetyl‐salicylic acid (ASA)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 2% ketoprofen (KTP)
Number of subjects: 33

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 1% ketoprofen (KTP)
Number of subjects: 33
Study: 16928616

Group type: EXPERIMENTAL
Intervention: Increased urinary podocyte mRNA excretion
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High synaptopodin mRNA levels
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: High nephrin mRNA levels
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Normal blood pressure, urinalysis, and serum creatinine concentration
Number of subjects: 15
Study: 14769712

Group type: EXPERIMENTAL
Intervention: Amiodarone, 200 mg/d
Number of subjects: 146

Group type: COMPARATOR
Intervention: Propafenone, 450 mg/d
Number of subjects: 146
Study: 11379374

Group type: EXPERIMENTAL
Intervention: Synthetic conjugated estrogen tablets
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 9135227

Group type: EXPERIMENTAL
Intervention: Alendronate (7.5 mg dissolved in 250 ml saline solution)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo saline infusions
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Alendronate (7.5 mg/day for three days, open label)
Number of subjects: 20
Study: 7955026

Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb (EZ-HT, 5 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Schwarz (SW-HT, 5 months)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Schwarz (SW-std, 10 months)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Edmonston-Zagreb (EZ-HT, 5 months) for females
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Schwarz (SW-HT, 5 months) for females
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-titre measles vaccine (EZ-HT, SW-HT)
Number of subjects: 0
Study: 3680601

Group type: EXPERIMENTAL
Intervention: Caffeine (64 mg) + Aspirin (800 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Caffeine (64 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin (800 mg)
Number of subjects: 0
Study: 28064163

Group type: EXPERIMENTAL
Intervention: Spironolactone 12.5-50 mg/day
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 27917793

Group type: EXPERIMENTAL
Intervention: i.v. furosemide (200‐300 mg bid) and 3% hypotonic saline solution (HSS) (once or twice a day)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: oral furosemide tablets (360‐520 mg bid) and salt (2.5 g bid)
Number of subjects: 78

Group type: COMPARATOR
Intervention: repeated large‐volume‐paracentesis (RLVP) with albumin infusion
Number of subjects: 78
Study: 24873894

Group type: EXPERIMENTAL
Intervention: Soybean leaf extracts (SLE) 2 g per day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Banaba extracts (BE) 300 mg per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (starch 2 g per day)
Number of subjects: 0
Study: 22854988

Group type: EXPERIMENTAL
Intervention: Platelet‐leukocyte membrane
Number of subjects: 80

Group type: COMPARATOR
Intervention: No platelet‐leukocyte membrane
Number of subjects: 80
Study: 19958442

Group type: EXPERIMENTAL
Intervention: EMD plus bone grafts
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: EMD plus membranes
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: EMD with bovine bone grafts
Number of subjects: 28

Group type: COMPARATOR
Intervention: EMD alone
Number of subjects: 28
Study: 18356794

Group type: EXPERIMENTAL
Intervention: Acupuncture plus usual GP care
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual GP care alone
Number of subjects: 30
Study: 15756156

Group type: EXPERIMENTAL
Intervention: Group 1: midazolam (0.015‐0.030 mg/kg) and sufentanil (0.15‐0.20 microg/kg)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Group 2: midazolam (0.15‐0.2 mg/kg) and continuous remifentanil infusion 0.5‐1 microg/kg/min followed by 0.05 microg/kg/min
Number of subjects: 65
Study: 12479634

Group type: EXPERIMENTAL
Intervention: Autogenous connective tissue graft (CT group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Acellular dermal matrix (ADM group)
Number of subjects: 30
Study: 10515145

Group type: EXPERIMENTAL
Intervention: Fuji Ortho LC (unetched enamel, wet condition)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fuji Ortho LC (unetched enamel, dry condition)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Resilience L3 (etched enamel)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Light Bond (etched enamel)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fuji Ortho LC (in vivo)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Conventional resins (in vivo)
Number of subjects: 30
Study: 7670590

Group type: EXPERIMENTAL
Intervention: Intracavernosal injection of prostaglandin E1 with RMRI penile clamp
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intracavernosal injection of prostaglandin E1 without RMRI penile clamp
Number of subjects: 0
Study: 2348457

Group type: EXPERIMENTAL
Intervention: High-demand preface
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Low-demand preface
Number of subjects: 126

Group type: COMPARATOR
Intervention: No-preface (control)
Number of subjects: 126
Study: 1267438

Group type: EXPERIMENTAL
Intervention: Buffered cephalothin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Unbuffered cephalothin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Diluent alone (5% dextrose in water)
Number of subjects: 12
Study: 31816191

Group type: EXPERIMENTAL
Intervention: 2 mL of 1:100,000 epinephrine injected intranasally
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: 2 mL of 1:200,000 epinephrine injected intranasally
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Topical 1:1000 epinephrine pledgets placed after injection of epinephrine
Number of subjects: 28
Study: 31037544

Group type: EXPERIMENTAL
Intervention: Fragility Index calculation
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Risk of Bias evaluation using Cochrane Tool 2.0
Number of subjects: 39
Study: 28646975

Group type: EXPERIMENTAL
Intervention: IY TCM training
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 42
Study: 26071656

Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 99

Group type: COMPARATOR
Intervention: Sham-CPAP
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Direct LDL-C
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: oxLDL
Number of subjects: 99
Study: 23150678

Group type: EXPERIMENTAL
Intervention: Insulin infusion at 4, 8, and 40 mU/m2 · min during a three-stage hyperinsulinemic/euglycemic clamp after dietary control and overnight insulin infusion.
Number of subjects: 50
Study: 21770925

Group type: EXPERIMENTAL
Intervention: USL255 (200 mg) in fasted conditions
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: USL255 (200 mg) in fed conditions
Number of subjects: 36

Group type: COMPARATOR
Intervention: Topamax (100 mg) administered 12 h apart
Number of subjects: 36
Study: 19325515

Group type: EXPERIMENTAL
Intervention: Praziquantel (75 mg/kg/d for 1 day) with albendazole (15 mg/kg/d for 7 days)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Albendazole (15 mg/kg/d for 7 days)
Number of subjects: 112
Study: 17661565

Group type: EXPERIMENTAL
Intervention: 6000 IU vitamin D3 plus 400 IU prenatal vitamin
Number of subjects: 19

Group type: COMPARATOR
Intervention: 400 IU vitamin D3/day (control)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 6400 IU vitamin D3/day
Number of subjects: 19

Group type: COMPARATOR
Intervention: Oral vitamin D supplementation (control for infants)
Number of subjects: 19
Study: 14974311

Group type: EXPERIMENTAL
Intervention: 4 litres PEG 4000
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 4 litres PEG 3350
Number of subjects: 140

Group type: COMPARATOR
Intervention: 90 ml sodium phosphate with an additional 2.5 litres of fluid
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Combined PEG solutions (PEG 4000 and PEG 3350)
Number of subjects: 140
Study: 11350539

Group type: EXPERIMENTAL
Intervention: Recocef (Julphar, UAE)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Ceclor (Eli Lilly, UK)
Number of subjects: 25
Study: 10771930

Group type: EXPERIMENTAL
Intervention: Regular transfusion therapy
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Chronic hypoxia and iron overload
Number of subjects: 71
Study: 7948455

Group type: EXPERIMENTAL
Intervention: White 1.5‐hr dawn simulation peaking at 250 lux
Number of subjects: 19

Group type: COMPARATOR
Intervention: Red 1.5‐hr dawn signal peaking at 2 lux
Number of subjects: 19
Study: 3286684

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30630184

Group type: EXPERIMENTAL
Intervention: Round window niche drilling combined with daily intratympanic methylprednisolone for 7 times
Number of subjects: 20

Group type: COMPARATOR
Intervention: Daily intratympanic methylprednisolone for 7 times
Number of subjects: 20
Study: 28526033

Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 26

Group type: COMPARATOR
Intervention: Insulin glargine
Number of subjects: 26
Study: 26114347

Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 23953030

Group type: EXPERIMENTAL
Intervention: Irinotecan 3-weekly 350 mg/m² (or 300 mg/m² if age >70 or performance status (PS)=2)
Number of subjects: 672

Group type: COMPARATOR
Intervention: Irinotecan 3-weekly 140 mg/m² (120 mg/m² if age >70 or PS=2) with ciclosporin 3 mg/kg t.d.s. for three days by mouth starting on the morning before irinotecan
Number of subjects: 672

Group type: EXPERIMENTAL
Intervention: Irinotecan
Number of subjects: 672

Group type: COMPARATOR
Intervention: Irinotecan plus ciclosporin
Number of subjects: 672
Study: 21050027

Group type: EXPERIMENTAL
Intervention: Nasal budesonide 100 μg, 1 puff per nostril twice a day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 18344568

Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16884530

Group type: EXPERIMENTAL
Intervention: Heated Humidifier (HH)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Heat and Moisture Exchanger (HME)
Number of subjects: 104
Study: 15640636

Group type: EXPERIMENTAL
Intervention: Inhaled isoflurane via the Anesthetic Conserving Device
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intravenous midazolam infusion
Number of subjects: 40
Study: 11699174

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide bleaching agent (Opalescence/Ultradent)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo agent (PLA)
Number of subjects: 30
Study: 9159691

Group type: EXPERIMENTAL
Intervention: Topical heparin eyedrops
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no eyedrops)
Number of subjects: 200
Study: 7960021

Group type: EXPERIMENTAL
Intervention: Borderline hypertension group
Number of subjects: 150
Study: 3371309

Group type: EXPERIMENTAL
Intervention: Transtelephonic coronary intervention system
Number of subjects: 238

Group type: COMPARATOR
Intervention: Standard medical care (control)
Number of subjects: 238
Study: 30730938

Group type: EXPERIMENTAL
Intervention: Single power posing session
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Daily power posing practice
Number of subjects: 41

Group type: COMPARATOR
Intervention: No practice (control)
Number of subjects: 41
Study: 28676071

Group type: EXPERIMENTAL
Intervention: Intervention (systematic FC distress screening, privileged contact with oncology nurse, liaison with family physician)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 120
Study: 26519345

Group type: EXPERIMENTAL
Intervention: DEX 0.7
Number of subjects: 508

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 508
Study: 23686706

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (20,000 IU - 40,000 IU per week)
Number of subjects: 893

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (1,000 mg)
Number of subjects: 893

Group type: COMPARATOR
Intervention: Placebo (for both vitamin D and testosterone RCTs)
Number of subjects: 893
Study: 21160218

Group type: EXPERIMENTAL
Intervention: Intramuscular lidocaine 1.5 mg · kg(‐1) administered into the deltoid muscle 10 min before anaesthesia induction
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine 1.5 mg · kg(‐1), 2 min before anaesthesia induction
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group received only propofol injection
Number of subjects: 75
Study: 19129263

Group type: EXPERIMENTAL
Intervention: Marching music
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Weather forecast
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ignoring auditory stimulus
Number of subjects: 20

Group type: COMPARATOR
Intervention: No auditory stimulus
Number of subjects: 20
Study: 17371412

Group type: EXPERIMENTAL
Intervention: Client-centered therapy
Number of subjects: 33

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 33
Study: 15726852

Group type: EXPERIMENTAL
Intervention: CTiP-fabricated frameworks directly to Brånemark implants
Number of subjects: 36

Group type: COMPARATOR
Intervention: Brånemark implant/abutment assemblies
Number of subjects: 36
Study: 11768928

Group type: EXPERIMENTAL
Intervention: Vaccination against varicella
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acyclovir, valacyclovir, famciclovir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Analgesics, tricyclic antidepressants, and other agents
Number of subjects: 0
Study: 9492664

Group type: EXPERIMENTAL
Intervention: Vitamin A (200,000 IU) plus 25 IU vitamin E
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control (25 IU vitamin E)
Number of subjects: 83
Study: 8116784

Group type: EXPERIMENTAL
Intervention: Training with a flashlight attached to the hook of the prosthesis to connect dots on paper
Number of subjects: 52

Group type: COMPARATOR
Intervention: Practice moving an equally weighted prosthesis without the light or dots
Number of subjects: 52
Study: 3046824

Group type: EXPERIMENTAL
Intervention: Isoprenaline 5 ng min‐1 kg‐1 infused over 30 min
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Isoprenaline 15 ng min‐1 kg‐1 infused over 30 min
Number of subjects: 6
Study: 29621810

Group type: EXPERIMENTAL
Intervention: HIIT in plain (GE)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: HIIT in uphill (GB)
Number of subjects: 17
Study: 26705299

Group type: EXPERIMENTAL
Intervention: Intraoperative cell salvage (CS)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Control (no cell salvage)
Number of subjects: 195
Study: 25636071

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 33,000 IU
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO)
Number of subjects: 40
Study: 23690420

Group type: EXPERIMENTAL
Intervention: Tamoxifen plus radiation therapy (TamRT)
Number of subjects: 636

Group type: COMPARATOR
Intervention: Tamoxifen alone (Tam)
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: TamRT
Number of subjects: 636

Group type: COMPARATOR
Intervention: Tam
Number of subjects: 636
Study: 20953559

Group type: EXPERIMENTAL
Intervention: Topical quercetin applied two to three dabs three times daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Benzydamine hydrochloride mouthwash used three times daily
Number of subjects: 40